| Contact, Site Public |
| Recruiting | 1/2 | 368 | Europe, Canada, Japan, US, RoW | Dazostinag, TAK-676, Pembrolizumab, Platinum, 5-fluorouracil | Takeda, Takeda Development Center Americas, Inc. (TDC Americas) | Solid Neoplasms | 01/26 | 01/26 | | |
| Active, not recruiting | 1/2 | 49 | Europe, Japan, US, RoW | TAK-981, Pembrolizumab | Takeda, Takeda Development Center Americas, Inc. | Advanced or Metastatic Solid Tumors | 11/25 | 11/25 | | |
NCT05886491: A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia |
|
|
| Recruiting | 1/2 | 53 | US | GDX012, Chemotherapy Agents | Takeda | Leukemia | 04/26 | 06/27 | | |
| Completed | 1 | 80 | US | TAK-105-a, TAK-105-a Placebo, TAK-105-b, TAK-105-b Placebo | Takeda | Healthy Volunteers | 06/23 | 06/23 | | |
| Completed | 1 | 24 | US | TAK-227 | Takeda | Healthy Volunteers | 06/23 | 06/23 | | |
NCT05602818: A Study of Soticlestat in Healthy Adult Nondependent Recreational Drug Users With Central Nervous System (CNS) Depressant Experience |
|
|
| Completed | 1 | 67 | US | Soticlestat 300 mg, Soticlestat 600 mg, Soticlestat 900 mg, Alprazolam, Placebo | Takeda | Healthy Volunteers | 06/23 | 07/23 | | |
NCT05995249: A Study of the Interaction of TAK-279 With Substances That Have an Impact on Metabolism in Healthy Adults |
|
|
| Completed | 1 | 172 | US | TAK-279, Erythromycin, Phenytoin, Efavirenz | Takeda | Healthy Volunteers | 12/23 | 12/23 | | |
NCT06132867: A Study to Compare the Relative Bioavailability of Brigatinib When Swallowed as a Solution Versus When Swallowed as a Tablet in Healthy Adults |
|
|
| Completed | 1 | 12 | US | Brigatinib, ALUNBRIG® | Takeda | Healthy Volunteers | 02/24 | 02/24 | | |
NCT04879849: A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers |
|
|
| Completed | 1 | 34 | US | Pembrolizumab, TAK-676, Image-guided radiation therapy | Takeda | Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms, Squamous Cell Carcinoma of Head and Neck | 04/24 | 04/24 | | |
NCT06258265: A Study of TAK-279 in Healthy Adults on the Effect on ECG Measurements |
|
|
| Recruiting | 1 | 120 | US | TAK-279, TAK-279 Placebo, Moxifloxacin, Moxifloxacin Placebo | Takeda | Healthy Volunteers | 06/24 | 07/24 | | |
NCT05976321: A Study of TAK-279 in Adults With or Without Liver Damage |
|
|
| Recruiting | 1 | 32 | US | TAK-279 | Takeda | Hepatic Impairment, Healthy Volunteers | 08/24 | 08/24 | | |
| Terminated | 1 | 14 | US | MT-0169 | Molecular Templates, Inc. | Relapsed and/or Refractory Multiple Myeloma | 12/23 | 12/23 | | |
NCT05976334: An Absorption, Distribution, Metabolism, Excretion (ADME) Study of [14C]Subasumstat in Adults With Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 10 | Europe | [14C] Subasumstat, TAK-981, Subasumstat | Takeda | Solid Tumors | 08/24 | 04/25 | | |
NCT06377228: A Study of TAK-007 in Adults With Refractory Lupus Nephritis (LN) |
|
|
| Not yet recruiting | 1 | 20 | NA | TAK-007, Chemotherapy Agents | Takeda | Refractory Lupus Nephritis | 04/29 | 04/29 | | |
| Recruiting | 1 | 24 | RoW | TAK-279, Placebo | Takeda | Healthy Volunteers | 12/24 | 12/24 | | |
NCT05992155: A Study of TAK-279 in Adults With or Without Kidney Problems |
|
|
| Completed | 1 | 24 | US | TAK-279 | Takeda | Renal Impairment, Healthy Volunteers | 05/24 | 05/24 | | |
NCT05891158: A Study About Fazirsiran in People With and Without Liver Problems |
|
|
| Recruiting | 1 | 41 | Europe | Fazirsiran, TAK-999 | Takeda | Hepatic Impairment | 04/25 | 04/25 | | |
| Active, not recruiting | 1 | 120 | Europe, US, RoW | Modakafusp alfa, TAK-573, Lenalidomide, Bortezomib, Carfilzomib, Daratumumab, Pomalidomide | Takeda | Multiple Myeloma | 01/24 | 06/24 | | |
NCT05702424: Evaluation of IGM-7354 in Adults With Relapsed and/or Refractory Cancer |
|
|
| Active, not recruiting | 1 | 50 | US | IGM-7354 | IGM Biosciences, Inc. | Solid Tumor | 02/26 | 03/26 | | |
NCT05174221: A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy |
|
|
| Active, not recruiting | 1 | 16 | Europe, Japan, US, RoW | Mezagitamab, TAK-079 | Takeda | Kidney Disease, Glomerulonephritis | 03/26 | 03/26 | | |
NCT04506619 / 2020-002726-84: Safety and Efficacy Outcomes Following Previously Administered Short-Term Treatment With SHP607 in Extremely Premature Infants |
|
|
| Terminated | N/A | 26 | Europe, US | No Intervention | Oak Hill Bio Ltd | Retinopathy of Prematurity (ROP), Intraventricular Hemorrhage, Bronchopulmonary Dysplasia, Chronic Lung Disease of Prematurity | 08/22 | 08/22 | | |
| Completed | N/A | 179 | Europe, Canada, RoW | | Takeda | Non-small Cell Lung Cancer (NSCLC) | 02/23 | 02/23 | | |
INTUITION-CPF, NCT04844593: A Study Using Artificial Intelligence to Identify Adults With Complex Perianal Fistulas Associated With Crohn's Disease |
|
|
| Completed | N/A | 32 | Europe | | Takeda | Crohn Disease, Rectal Fistula | 02/23 | 04/24 | | |
NCT05795361: Post-trial Access Program of Idursulfase-IT Along With Elaprase in Children With Hunter Syndrome |
|
|
| Available | N/A | | Europe, US, RoW | Idursulfase-IT, HGT-2310, TAK-609 | Takeda | Hunter Syndrome | | | | |
NCT05265078: A Study on Estimated Risks of Certain Adverse Events in Adults With Von Willebrand Disease (VWD) Treated With Veyvondi |
|
|
| Completed | N/A | 102 | Europe | | Takeda | Von Willebrand Disease (VWD) | 04/23 | 04/23 | | |
DOrianT, NCT04659798: A Study to Investigate the Relationship Between Duration of Treatment and Response in Patients With Multiple Myeloma (MM) or Systemic AL Amyloidosis Treated in Real-life Practice |
|
|
| Completed | N/A | 240 | Europe | | Takeda | Multiple Myeloma, Immunoglobulin Light-chain Amyloidosis | 04/23 | 08/23 | | |
NCT04877431: A Study of Teduglutide (Revestive®) in Children, Teenagers and Adults With Short Bowel Disease |
|
|
| Completed | N/A | 45 | RoW | | Takeda | Short Bowel Syndrome | 06/23 | 06/23 | | |
NCT04583007: Expanded Access for the Prevention of Acute Attacks of 1) Hereditary Angioedema (HAE) in Children and 2) Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) in Teenagers and Adults |
|
|
| No Longer Available | N/A | | Europe, Canada, US | Lanadelumab 150 mg, TAK-743, SHP643, DX-2930, Lanadelumab 300 mg | Shire, Takeda Development Center Americas, Inc. | Hereditary Angioedema (HAE), Angioedema | | | | |
| Completed | N/A | 48 | RoW | | Takeda | Angioedemas, Hereditary | 08/23 | 08/23 | | |
ermEX-20, NCT05419700: A Spanish Medical Record Review of Clinical Characteristics and Outcomes in Non-small Cell Lung Cancer Participants With EGFR Exon 20 Insertion |
|
|
| Completed | N/A | 76 | Europe | | Takeda | Non-small Cell Lung Cancer (NSCLC) | 09/23 | 09/23 | | |
NCT05695560: A Survey to Describe the Experience and Unmet Needs of Persons Living With Von Willebrand Disease (VWD) and Their Caregivers |
|
|
| Completed | N/A | 12 | Canada | No Intervention | Takeda | Von Willebrand Disease (VWD) | 11/23 | 11/23 | | |
| Active, not recruiting | N/A | 2800 | RoW | | Takeda | Lymphoma | 12/24 | 12/24 | | |
NCT05489640: A Study in Adults With Hereditary Angioedema (HAE) Who Currently Receive Icatibant at Home |
|
|
| Recruiting | N/A | 100 | Europe | No Intervention | Takeda | Hereditary Angioedema (HAE) | 06/24 | 06/24 | | |
PROSPECT, NCT05578417: A Study to Review the Treatment and Outcomes of Teenagers and Adults With Non-histaminergic Angioedema With Normal C1 Inhibitor in Canada |
|
|
| Recruiting | N/A | 150 | Canada | No Intervention | Takeda | Hereditary Angioedema (HAE), Angioedema | 03/24 | 06/24 | | |
NCT03824522: Post Marketing Surveillance Study for ADYNOVATE in South Korea |
|
|
| Completed | N/A | 341 | RoW | ADYNOVATE, PEGylated rFVIII | Takeda, Takeda Pharma Korea Co. Ltd. | Hemophilia A | 01/24 | 01/24 | | |
NCT04885920: A Study on Administration Choices of Vedolizumab and Outcomes for Adults With Inflammatory Bowel Disease (IBD) (VARIETY - CROATIA AND SLOVENIA) |
|
|
| Completed | N/A | 120 | Europe, RoW | | Takeda | Inflammatory Bowel Diseases, Crohns Disease, Colitis, Ulcerative | 03/24 | 03/24 | | |
| Recruiting | N/A | 1000 | RoW | | Takeda | Lymphoma | 06/24 | 06/24 | | |
NCT05371028: A Study of Teduglutide (Revestive®) in Participants With Short Bowel Syndrome (SBS) in Canada |
|
|
| Recruiting | N/A | 100 | Canada | Non-interventional Study | Takeda | Short Bowel Syndrome (SBS) | 07/24 | 07/24 | | |
| Active, not recruiting | N/A | 50 | Europe | No intervention | Takeda | Fabry Disease | 04/24 | 04/24 | | |
| Recruiting | N/A | 3000 | RoW | No Intervention | Jeil Pharmaceutical Co., Ltd. | Constipation | 05/24 | 11/24 | | |
NCT04872491: A Study of Vedolizumab in Adults in Real-World Practice |
|
|
| Active, not recruiting | N/A | 500 | RoW | | Takeda | Colitis, Ulcerative, Crohn Disease | 07/24 | 07/24 | | |
DRALEGA, NCT05982717: A Study to Gather Information About Overall Occurrence and New Cases of Dravet and Lennox-Gastaut Syndromes in Children, Teenagers and Adults in Spain |
|
|
| Recruiting | N/A | 250 | Europe | No intervention | Takeda | Dravet Syndrome (DS), Lennox-Gastaut Syndrome (LGS) | 05/24 | 05/24 | | |
NCT04840680: A Study of Real-World Use of Ixazomib Citrate in People With Multiple Myeloma (MM) |
|
|
| Recruiting | N/A | 165 | RoW | No Intervention | Takeda | Multiple Myeloma | 06/24 | 06/24 | | |
NCT05886478: A Study in Adults With Cutaneous T-cell Lymphoma (CTCL) Retreated With Brentuximab Vedotin |
|
|
| Recruiting | N/A | 50 | Europe | No intervention | Takeda | T-Cell Lymphoma | 06/24 | 06/24 | | |
| Withdrawn | N/A | 30 | Europe | No Intervention | Takeda | Metachromatic Leukodystrophy (MLD) | 07/24 | 07/24 | | |
NCT06346899: A Study of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) in Persons With HAE in China |
|
|
| Not yet recruiting | N/A | 130 | RoW | No intervention | Takeda | Hereditary Angioedema (HAE) | 08/25 | 08/25 | | |
ENABLE, NCT04130191: A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II |
|
|
| Active, not recruiting | N/A | 140 | Europe, RoW | | Shire, Takeda Development Center Americas, Inc. | Hereditary Angioedema (HAE) | 09/24 | 09/24 | | |
LANDSCAPE, NCT04943796: A Study to Learn About the Occurrence of ADHD in Adults With Mental Conditions and Their Quality of Life |
|
|
| Recruiting | N/A | 576 | Europe, Canada | | Takeda | Attention Deficit Hyperactivity Disorder (ADHD) | 09/24 | 09/24 | | |
| Active, not recruiting | N/A | 482 | RoW | | Takeda | Multiple Myeloma, Neoplasms, Plasma Cell | 09/25 | 09/25 | | |
NCT06104878: A Study in Adults With Advanced Classical Hodgkin's Lymphoma (cHL) in Brazil Treated With Brentuximab Vedotin Together With Chemotherapy Compared to Chemotherapy Alone |
|
|
| Withdrawn | N/A | 200 | RoW | No Intervention | Takeda | Hodgkin Lymphoma | 10/24 | 10/24 | | |
ELEGANT, NCT05737849: A Study to Learn About the Tests Looking for a Gene Mutation in Adults With Lung Cancer in China |
|
|
| Withdrawn | N/A | 10800 | RoW | No Intervention | Takeda | Non-small Cell Lung Cancer (NSCLC) | 12/24 | 12/24 | | |
NCT04837222: A Study of Brentuximab Vedotin in Adults With CD30-positive Lymphoma |
|
|
| Recruiting | N/A | 1000 | RoW | No Intervention | Takeda | Lymphoma | 01/25 | 01/25 | | |
| Active, not recruiting | N/A | 72 | Europe, Canada, RoW | No Intervention | Takeda | Crohn's Disease | 01/25 | 01/25 | | |
PEDS, NCT04721366: A Study of Velaglucerase Alfa (VPRIV) Given as Standard Patient Care in Young Children With Gaucher Disease |
|
|
| Completed | N/A | 11 | US | Standard of Care, SOC | Takeda | Gaucher Disease | 04/23 | 04/23 | | |
NCT05626088: A Study in Adults With Inflammatory Bowel Disease (IBD) Receiving Vedolizumab in the Patient Support Program (PSP) in Brazil |
|
|
| Recruiting | N/A | 2160 | RoW | No Intervention | Takeda | Ulcerative Colitis, Crohn's Disease | 01/25 | 01/25 | | |
HyMMy, NCT05879757: Real-world Usage of HyQvia in Multiple Myeloma Adults With Secondary Immunodeficiency |
|
|
| Recruiting | N/A | 100 | Europe, RoW | No Intervention | Takeda | Multiple Myeloma, Secondary Immunodeficiency (SID) | 07/25 | 03/26 | | |
| Recruiting | N/A | 111 | RoW | | Takeda | Multiple Myeloma | 08/25 | 08/25 | | |
VARIETY, NCT05384080: A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Practice in Poland |
|
|
| Active, not recruiting | N/A | 165 | Europe | | Takeda | Inflammatory Bowel Disease (IBD), Crohn's Disease, Ulcerative Colitis | 08/25 | 08/25 | | |
NCT05013190: A Study of NINLARO® in Chinese Adults With Multiple Myeloma |
|
|
| Recruiting | N/A | 320 | RoW | No intervention | Takeda | Multiple Myeloma | 10/25 | 10/25 | | |
NCT04961840: A Study to Assess Maternal and Fetal Outcomes After Taking Prucalopride During Pregnancy |
|
|
| Active, not recruiting | N/A | 100 | US | No Intervention | Takeda | Constipation, Pregnancy | 12/25 | 12/25 | | |
NCT04799496: A Study of Kynteles Injection (Vedolizumab) in Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease or Chronic Pouchitis |
|
|
| Recruiting | N/A | 600 | RoW | | Takeda | Inflammatory Bowel Diseases, Colitis, Ulcerative, Crohn Disease | 01/26 | 01/26 | | |
| Recruiting | N/A | 40 | Europe | | Takeda | Hereditary Angioedema (HAE) | 03/26 | 03/26 | | |
NCT04869280: Post-Marketing Study of Prucalopride Safety In Pregnancy |
|
|
| Recruiting | N/A | 616 | US | No Intervention | Takeda, The Organization of Teratology Information Specialists | Chronic Idiopathic Constipation (CIC) | 05/26 | 05/26 | | |
| Recruiting | N/A | 70 | Europe | No Intervention | Takeda | Hodgkin Lymphoma | 06/26 | 06/26 | | |
NCT04838522: A Study of Prucalopride in Breastfeeding Women With Constipation |
|
|
| Recruiting | N/A | 12 | US | No Intervention | Takeda, UC San Diego Human Milk Research Biorepository | Chronic Idiopathic Constipation (CIC) | 12/26 | 12/26 | | |
NCT01034969: Firazyr® Patient Registry (Icatibant Outcome Survey - IOS) |
|
|
| Recruiting | N/A | 3000 | Europe, RoW | | Shire, Takeda Development Center Americas, Inc. | Hereditary Angioedema (HAE) | 01/27 | 01/27 | | |
ENTIRETY, NCT05735327: A Study of Brigatinib as Preferred First Therapy for Adults With Non-Small Cell Lung Cancer (NSCLC) |
|
|
| Recruiting | N/A | 50 | Europe | No intervention | Takeda | Non-small Cell Lung Cancer (NSCLC) | 06/27 | 06/27 | | |
NCT05428345: A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea |
|
|
| Recruiting | N/A | 600 | RoW | | Takeda | Ulcerative Colitis, Crohn's Disease, Inflammatory Bowel Disease (IBD) | 11/27 | 11/27 | | |
NCT04158934: A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A |
|
|
| Active, not recruiting | N/A | 207 | Europe, US, RoW | ADYNOVI/ADYNOVATE, Antihaemophilic Factor [Recombinant] PEGylated rurioctocog alfa pegol, TAK-660, BAX 855 | Baxalta now part of Shire | Hemophilia A | 02/30 | 02/30 | | |
| Active, not recruiting | N/A | 1340 | Europe, Canada, US | No intervention | Takeda, Takeda Development Center Americas, Inc. | Hypoparathyroidism | 11/34 | 11/34 | | |
| Lev, Nirit |
| Recruiting | 1/2 | 65 | Europe, RoW | VO659 | Vico Therapeutics B. V., VICO Therapeutics B.V. | Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 3, Huntington Disease | 09/25 | 09/25 | | |
| Rao, Pooja |
FAST, NCT06174649: Fast Antibiotic Susceptibility Testing for Gram Negative Bacteremia Trial |
|
|
| Recruiting | N/A | 900 | Europe, RoW | Reveal | Duke University, National Institute of Allergy and Infectious Diseases (NIAID), Parexel, BioMérieux | Gram-negative Bacteremia, Bloodstream Infection | 05/25 | 06/25 | | |
| Alessio, Maria |
NCT04527380 / 2018-000681-10: A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis |
|
|
| Active, not recruiting | 3 | 100 | Europe, RoW | Ixekizumab, LY2439821, Adalimumab | Eli Lilly and Company | Juvenile Psoriatic Arthritis, Enthesitis Related Arthritis | 02/24 | 04/28 | | |
NCT04088396 / 2017-004495-60: A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA) |
|
|
| Recruiting | 3 | 58 | Europe, Japan, RoW | Baricitinib, LY3009104, Tocilizumab | Eli Lilly and Company | Systemic Juvenile Idiopathic Arthritis | 10/25 | 10/25 | | |
| Recruiting | 3 | 190 | Europe, Japan, RoW | Baricitinib, LY3009104 | Eli Lilly and Company | Juvenile Idiopathic Arthritis | 12/30 | 12/30 | | |
| Uziel, Yosef |
NCT04088396 / 2017-004495-60: A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA) |
|
|
| Recruiting | 3 | 58 | Europe, Japan, RoW | Baricitinib, LY3009104, Tocilizumab | Eli Lilly and Company | Systemic Juvenile Idiopathic Arthritis | 10/25 | 10/25 | | |
| Recruiting | 3 | 190 | Europe, Japan, RoW | Baricitinib, LY3009104 | Eli Lilly and Company | Juvenile Idiopathic Arthritis | 12/30 | 12/30 | | |
| Maor, Gil Shechter |
NCT05782296: Noninvasive Monitoring of Uterine Activity and Fetal Heart Rate |
|
|
| Recruiting | N/A | 100 | US, RoW | TrueLabor | OB-Tools Ltd. | Fetal Heart Rate or Rhythm Abnormality Affecting Newborn During Labor, Uterine Contractions, Obstetric Complication | 04/24 | 04/24 | | |
| Vishlitzky, Victor |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
| Not yet recruiting | 3 | 300 | Europe, Canada, US, RoW | Tirzepatide, LY3298176, Placebo | Eli Lilly and Company | Obesity, Weight Gain | 05/27 | 06/27 | | |
| Active, not recruiting | 3 | 15374 | Europe, Canada, Japan, US, RoW | Tirzepatide, LY3298176, Placebo | Eli Lilly and Company | Obesity, Overweight | 10/27 | 10/27 | | |
| Jarchowsky, Osnat |
XPORT-MM-028, NCT04414475 / 2020-000821-22: A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM, and Seli and Pomalidomide + LDD in Relapsed Refractory MM |
|
|
| Recruiting | 2 | 141 | Europe, RoW | Selinexor, KPT-330, XPOVIO, Dexamethasone, Decadron, Bortezomib, Velcade, Pomalidomide, Imnovid | Karyopharm Therapeutics Inc | Multiple Myeloma, Refractory | 06/24 | 06/25 | | |
| Cattalini, Marco |
NCT04527380 / 2018-000681-10: A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis |
|
|
| Active, not recruiting | 3 | 100 | Europe, RoW | Ixekizumab, LY2439821, Adalimumab | Eli Lilly and Company | Juvenile Psoriatic Arthritis, Enthesitis Related Arthritis | 02/24 | 04/28 | | |
NCT04088396 / 2017-004495-60: A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA) |
|
|
| Recruiting | 3 | 58 | Europe, Japan, RoW | Baricitinib, LY3009104, Tocilizumab | Eli Lilly and Company | Systemic Juvenile Idiopathic Arthritis | 10/25 | 10/25 | | |
| Recruiting | 3 | 190 | Europe, Japan, RoW | Baricitinib, LY3009104 | Eli Lilly and Company | Juvenile Idiopathic Arthritis | 12/30 | 12/30 | | |
| Maimon-Rabinovich, Natalie |
PROPHETIC, NCT04056247: Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments |
|
|
| Recruiting | N/A | 2000 | Europe, US, RoW | Plasma sample collection | OncoHost Ltd. | Stage IV Non-small Cell Lung Cancer, Stage IV Malignant Melanoma, Stage IV Small Cell Lung Cancer, Stage III Malignant Melanoma | 10/29 | 10/29 | | |
| Mishaly, Moshe |
PROPHETIC, NCT04056247: Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments |
|
|
| Recruiting | N/A | 2000 | Europe, US, RoW | Plasma sample collection | OncoHost Ltd. | Stage IV Non-small Cell Lung Cancer, Stage IV Malignant Melanoma, Stage IV Small Cell Lung Cancer, Stage III Malignant Melanoma | 10/29 | 10/29 | | |
| Furuya, Ken |
NCT05507216: ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2 |
|
|
| Recruiting | 3 | 612 | Europe, Canada, Japan, US, RoW | ABX464, Obefazimod, Placebo | Abivax S.A. | Ulcerative Colitis | 12/24 | 02/25 | | |
| Recruiting | 3 | 1050 | Europe, Canada, Japan, US, RoW | ABX464, Obefazimod, Placebo | Abivax S.A. | Ulcerative Colitis | 01/26 | 06/26 | | |
| Active, not recruiting | 3 | 859 | Europe, Canada, Japan, US, RoW | Bepirovirsen, Placebo | GlaxoSmithKline, GlaxoSmithKline Research & Development Limited | Chronic Hepatitis B, Hepatitis B, Chronic | 11/25 | 05/26 | | |
| Bauer, Tzofia |
| Active, not recruiting | N/A | 252 | RoW | | MYOR Ltd., Meir Medical Center, The Baruch Padeh Medical Center, Poriya | Atopic Dermatitis | 05/23 | 05/24 | | |
| Kuchuk, Iryna |
| Active, not recruiting | 3 | 368 | Europe, US, RoW | Abemaciclib, Fulvestrant, Placebo | Eli Lilly and Company, Eli Lilly and Company | Breast Neoplasm, Neoplasm Metastasis | 02/24 | 02/26 | | |
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
| Omelchenko, Alex |
| Recruiting | N/A | 3000 | Europe, Japan, RoW | Cardiac Resynchronization Therapy (CRT) | Biotronik SE & Co. KG | Heart Failure | 12/24 | 06/25 | | |
NCT04613544: Assess Safety, Efficacy and Usability of Application for Atrial Fibrillation Vocal Marker |
|
|
| Recruiting | N/A | 400 | RoW | Voice Assist Arrhythmia Monitoring (VAAM) | Cardiokol Ltd | Atrial Fibrillation | 08/21 | 12/21 | | |
| Kutiel, Talia Shentzer |
SPRINT, NCT04256707 / 2021-000617-16: Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment |
|
|
| Recruiting | 1/2 | 120 | RoW | Selinexor 100 mg, Xpovio®, Docetaxel, Taxotere®, Pembrolizumab, Keytruda®, FOLFIRI, Selinexor 40 mg, Selinexor 80 mg, Selinexor 60 mg | Karyopharm Therapeutics Inc | Non-Small Cell Lung Carcinoma (NSCLC), Colorectal Cancer (CRC), Other Solid Tumors | 03/25 | 03/25 | | |
| Diamant, Avital |
NCT05782296: Noninvasive Monitoring of Uterine Activity and Fetal Heart Rate |
|
|
| Recruiting | N/A | 100 | US, RoW | TrueLabor | OB-Tools Ltd. | Fetal Heart Rate or Rhythm Abnormality Affecting Newborn During Labor, Uterine Contractions, Obstetric Complication | 04/24 | 04/24 | | |
| Einbinder, Yael |
NCT04808011: A Single Arm, Multi-Center Study To Evaluate The Intelligent Dialysis Assistant (IDA) |
|
|
| Recruiting | N/A | 20 | RoW | Intelligent Dialysis Assistant (IDA) | liberDi Ltd. | Chronic Kidney Disease Stage 5 | 12/23 | 12/23 | | |
| Nemets, Anatoly |
| Recruiting | 3 | 550 | Europe, Canada, US, RoW | Tamibarotene, SY-1425, Placebo, Azacitidine | Syros Pharmaceuticals | Myelodysplastic Syndromes | 11/24 | 02/29 | | |
XPORT-MM-028, NCT04414475 / 2020-000821-22: A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM, and Seli and Pomalidomide + LDD in Relapsed Refractory MM |
|
|
| Recruiting | 2 | 141 | Europe, RoW | Selinexor, KPT-330, XPOVIO, Dexamethasone, Decadron, Bortezomib, Velcade, Pomalidomide, Imnovid | Karyopharm Therapeutics Inc | Multiple Myeloma, Refractory | 06/24 | 06/25 | | |
